Xylem Inc. (XYL - Free Report) seems to have lost its sheen to weakness in commercial and industrial markets, soft orders, woes related to Coronavirus and others headwinds. Also, lowered earnings estimates and weak price performance add to concerns.
The company has a market capitalization of $15.4 billion and a Zacks Rank #5 (Strong Sell) at present. It belongs to the Zacks Manufacturing – General Industrial industry.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We believe that the industry is suffering from adverse impacts of cost escalation, induced by freight charges, tariff woes and high labor costs. Also, global uncertainties, unfavorable movements in foreign currencies and softness in industrial production in the United States add to the woes.
In the last reported quarter, the company’s earnings of 89 cents met estimates, while sales lagged the same by 0.7%. It has a negative earnings surprise of 2.59%, on average, for the last four quarters.
In the past three months, Xylem’s shares have gained 15.2% compared with the industry’s growth of 9%.
Factors Affecting Investment Appeal
End-Market Weakness: The company posted weaker-than-expected top-line results in fourth-quarter 2019, with sales lagging estimates by 0.7%. On a year-over-year basis, organic sales for the industrial market declined 3%, while that for commercial and residential fell 5% and 2%, respectively.
For 2020, the company expects industrial organic sales to be flat year over year. Its performance will likely be impacted by soft mining/oil and gas market, subdued business in Europe, and economic uncertainty and geopolitical issues in the Middle East. Also, the short-cycle business in North America is expected to be soft in the first half.
Additionally, Xylem believes that operating conditions will be soft for commercial markets in the first half of 2020.
Cost & Expenses: In fourth-quarter 2019, the company’s operating margin was adversely impacted by cost inflation to the tune of 3 percentage points. Also, investments, forex woes, acquisitions/divestments, mix and others had adverse impacts on margin. We believe that the persistence of these cost-related woes might have adverse impacts on margin.
For the first quarter of 2020, Xylem predicts an adjusted operating margin of 8-9%, suggesting a decline from 10.8% reported in the previous-year quarter.
Woes Related to International Presence: Presence in the United States, the Asia Pacific, Europe and other nations exposed Xylem to geopolitical issues, macroeconomic challenges and unfavorable movements in foreign currencies. In fourth-quarter 2019, forex woes adversely affected the company’s earnings by two cents per share.
Persistence of such issues might pose concerns for Xylem.
Poor Projection: For the first half of 2020, Xylem predicts earnings of 40% of the annual projection of $2.96-$3.16 per share. This compares unfavorably with 43% of annual earnings realized in the first half of 2019. Also, the company expects a low-single-digit decline in organic sales in the first half due to soft orders, strong comparisons in the year-ago period and uncertainty over Coronavirus in China. Specifically, organic sales are expected to decline 3-5% in the first quarter of 2010.
Bottom-Line Estimate Trend: The Zacks Consensus Estimate for Xylem’s earnings has been revised downward in the past seven days. The Zacks Consensus Estimate for earnings per share is currently pegged at $3.08 for 2020 and $3.53 for 2021, down 7.2% and 5.1% from the seven-day-ago figures.
Also, earnings estimates of 43 cents per share for the first quarter and 78 cents for the second quarter suggest declines of 29.5% and 8.2% from the respective seven-day-ago figures.
Xylem Inc. Price and Consensus
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Xylem Inc. (XYL - Free Report) seems to have lost its sheen to weakness in commercial and industrial markets, soft orders, woes related to Coronavirus and others headwinds. Also, lowered earnings estimates and weak price performance add to concerns.
The company has a market capitalization of $15.4 billion and a Zacks Rank #5 (Strong Sell) at present. It belongs to the Zacks Manufacturing – General Industrial industry.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We believe that the industry is suffering from adverse impacts of cost escalation, induced by freight charges, tariff woes and high labor costs. Also, global uncertainties, unfavorable movements in foreign currencies and softness in industrial production in the United States add to the woes.
In the last reported quarter, the company’s earnings of 89 cents met estimates, while sales lagged the same by 0.7%. It has a negative earnings surprise of 2.59%, on average, for the last four quarters.
In the past three months, Xylem’s shares have gained 15.2% compared with the industry’s growth of 9%.
Factors Affecting Investment Appeal
End-Market Weakness: The company posted weaker-than-expected top-line results in fourth-quarter 2019, with sales lagging estimates by 0.7%. On a year-over-year basis, organic sales for the industrial market declined 3%, while that for commercial and residential fell 5% and 2%, respectively.
For 2020, the company expects industrial organic sales to be flat year over year. Its performance will likely be impacted by soft mining/oil and gas market, subdued business in Europe, and economic uncertainty and geopolitical issues in the Middle East. Also, the short-cycle business in North America is expected to be soft in the first half.
Additionally, Xylem believes that operating conditions will be soft for commercial markets in the first half of 2020.
Cost & Expenses: In fourth-quarter 2019, the company’s operating margin was adversely impacted by cost inflation to the tune of 3 percentage points. Also, investments, forex woes, acquisitions/divestments, mix and others had adverse impacts on margin. We believe that the persistence of these cost-related woes might have adverse impacts on margin.
For the first quarter of 2020, Xylem predicts an adjusted operating margin of 8-9%, suggesting a decline from 10.8% reported in the previous-year quarter.
Woes Related to International Presence: Presence in the United States, the Asia Pacific, Europe and other nations exposed Xylem to geopolitical issues, macroeconomic challenges and unfavorable movements in foreign currencies. In fourth-quarter 2019, forex woes adversely affected the company’s earnings by two cents per share.
Persistence of such issues might pose concerns for Xylem.
Poor Projection: For the first half of 2020, Xylem predicts earnings of 40% of the annual projection of $2.96-$3.16 per share. This compares unfavorably with 43% of annual earnings realized in the first half of 2019. Also, the company expects a low-single-digit decline in organic sales in the first half due to soft orders, strong comparisons in the year-ago period and uncertainty over Coronavirus in China. Specifically, organic sales are expected to decline 3-5% in the first quarter of 2010.
Bottom-Line Estimate Trend: The Zacks Consensus Estimate for Xylem’s earnings has been revised downward in the past seven days. The Zacks Consensus Estimate for earnings per share is currently pegged at $3.08 for 2020 and $3.53 for 2021, down 7.2% and 5.1% from the seven-day-ago figures.
Also, earnings estimates of 43 cents per share for the first quarter and 78 cents for the second quarter suggest declines of 29.5% and 8.2% from the respective seven-day-ago figures.
Xylem Inc. Price and Consensus
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on NDSN - FREE
Get the latest research report on B - FREE
Get the latest research report on XYL - FREE
Get the latest research report on TNC - FREE